Aditxt, Inc. ADTX

ADTX Company Overview

Aditxt, Inc. is a publicly traded biotechnology company focused on developing and commercializing technologies that address immune system modulation, diagnostics, and precision health monitoring. The company operates within the biotechnology and life sciences industries, with an emphasis on early disease detection, immune tolerance, and health data-driven insights. Its business model centers on advancing proprietary platforms through internal development, subsidiaries, and strategic partnerships, rather than on commercialized pharmaceutical products at scale.

The company’s primary revenue drivers to date have consisted of research collaborations, technology licensing arrangements, and capital formation activities, as its core programs remain largely in development stages. Aditxt positions itself as a platform innovator seeking to integrate immune monitoring, diagnostics, and therapeutic reprogramming to address chronic disease risk. Founded in 2017, the company has evolved from a single technology focus into a multi-subsidiary structure intended to diversify scientific risk and expand potential commercialization pathways.